<ul><li>EU approval is based on two Phase III studies showing Cosentyx&reg; provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1</li><li>Moderate-to-severe psoriasis affects more than 350,000 children worldwide2, with the physical and psychological burden disrupting important formative years3</li><li>Cosentyx is a proven brand, supported by long-term five-year sustained efficacy and safety data across psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), over 100 studies and with more than 340,000 patients treated worldwide since launch4,5,6,7</li><li>Approval reinforces Cosentyx leadership in immuno-dermatology and rheumatology, following recent EU approval in non-radiographic axial spondyloarthritis (nr-axSpA), with plans to expand to 10 indications over the next 10 years</li></ul>Basel, August 3, 2020 &mdash; Novartis, a leader in immuno-dermatology and rheumatology, today announced the European Commission (EC) has granted the approval for Cosentyx&reg; (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to &lt;18 years. The recommended dose for children up to 50 kg is 75 mg (without a lower weight restriction), and 150 mg for children 50 kg and over (150 mg as a starting dose, which may be increased to 300 mg, if needed).&ldquo;Psoriasis is a life-long debilitating disease that significantly impacts children&rsquo;s quality of life, both physically and emotionally. There are only a few approved treatment options available for the pediatric population and so it is important to broaden the adult therapeutic options out to children when possible,&rdquo; said Professor Christine Bodemer, Head of the Department of Dermatology, Necker&ndash;Enfants Malades Hospital, Paris. &ldquo;This approval means Cosentyx is now available in Europe for children and adolescents, and will provide an additional option to quickly gain relief from their symptom burden and to significantly improve their quality of life.&rdquo;The approval is based on two Phase III international studies in children and adolescents aged 6 to &lt;18 years. The studies showed that both low-dose (75&ndash;150 mg) and high-dose (75&ndash;300 mg) of Cosentyx were highly efficacious in rapidly improving skin symptoms and quality of life, with a favorable safety profile up to 52 weeks1.&ldquo;The impact of psoriasis on children is much deeper than skin and can potentially lead to life course impairment,&rdquo; said Todd Fox, Global Head of Medical Affairs Immunology, Hepatology and Dermatology at Novartis. &ldquo;This is the second European approval this year for Cosentyx, which also has approvals across four adult indications, reinforcing our commitment to reimagine medicine for both pediatric and adult patients.&rdquo;Children with psoriasis have a poorer quality of life than their peers due to symptoms such as itching and fatigue, in addition to feelings of stigmatization. These in turn may affect their emotional wellbeing and performance at school8.&ldquo;Children with psoriasis are susceptible to bullying, name-calling and shaming at school, leading to higher rates of depression and anxiety than their peers,&rdquo; said Jan Koren, President of the European patient group EUROPSO. &ldquo;We welcome this approval, as there is a need for additional treatment options that can help give children the freedom to enjoy full and active lives by improving psoriasis symptoms and thus overall quality of life.&rdquo;Novartis is working closely with all stakeholders to ensure that eligible European pediatric patients can start benefitting from Cosentyx as quickly as possible. Novartis will also be seeking approval for Cosentyx for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to &lt;18 years in a number of other countries including Australia, Canada, Japan and the US.About psoriasis Psoriasis is a life-long debilitating systemic inflammatory disease that significantly impacts patients&rsquo; quality of life, both physically and emotionally9. One-third of psoriasis cases begin in childhood and of these the onset is most common during adolescence10. Moderate-to-severe psoriasis affects more than 350,000 children worldwide and may impact children &ldquo;deeper than the skin&rdquo;, with the physical and psychological burden of psoriasis disrupting important formative years2. The incidence of pediatric psoriasis has more than doubled between 1970 and 2000 in the US and an upward trend in incidence of psoriasis has been observed in several countries9,10. There are only a few approved treatment options available and the unmet medical need remains high3.About the study data The two Phase III international studies in children and adolescents aged 6 to &lt;18 years consisted of one open‑label, two-arm, parallel‑group, multicentre study in children with moderate-to-severe plaque psoriasis and one randomized, double-blind, placebo and etanercept-controlled study in children with severe plaque psoriasis. Dosing regimens of Cosentyx were stratified by weight.In children with moderate-to-severe plaque psoriasis, the low dose of Cosentyx provided fast and strong skin clearance, with 93% achieving Psoriasis Area Severity Index (PASI) 75 as early as Week 12, 69% achieving PASI 90 at Week 12 and 88% at Week 24, 59.5% achieving completely clear skin (PASI 100) by Week 12 and 67% by Week 24. In patients with severe psoriasis, the low dose of Cosentyx ensured sustained skin clearance through Week 52, with PASI 90 achieved in 75% of patients1. Differences in PASI 75 in patients with severe psoriasis treated with Cosentyx were seen as early as Week 4 and in patients with moderate-to-severe psoriasis as early as Week 2.Half of children with moderate-to-severe plaque psoriasis treated with the low dose of Cosentyx reported complete relief from symptom burden of psoriasis on their quality of life as early as Week 12, as measured by Children&#39;s Dermatology Life Quality Index (CDLQI) 0/1 responses. In children with severe plaque psoriasis treated with the low dose of Cosentyx, 44.7% reported complete relief by Week 12, with 60.6% by Week 52.Cosentyx safety profile of both the low dose and high dose is comparable and consistent with the established adult psoriasis indication. No new safety signals were observed in children.About Cosentyx (secukinumab) Cosentyx is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the systemic inflammation and development of moderate-to-severe plaque psoriasis, PsA, AS and nr-axSpA11,12,13.Cosentyx is backed by more than 12 years of clinical experience and long-term five-year data across three indications of psoriasis, PsA and AS, as well as data from real world evidence14-19. These data strengthen the unique position of Cosentyx as a rapid and long-lasting comprehensive treatment across axial spondyloarthritis, PsA and psoriatic disease, with more than 340,000 patients treated worldwide with Cosentyx since launch4,19.Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as &ldquo;potential,&rdquo; &ldquo;can,&rdquo; &ldquo;will,&rdquo; &ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;seek,&rdquo; &ldquo;look forward,&rdquo; &ldquo;believe,&rdquo; &ldquo;committed,&rdquo; &ldquo;investigational,&rdquo; &ldquo;pipeline,&rdquo; &ldquo;launch,&rdquo; or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG&rsquo;s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.About Novartis Novartis is reimagining medicine to improve and extend people&rsquo;s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world&rsquo;s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at <a href="https://www.novartis.com">https://www.novartis.com</a>.Novartis is on Twitter. Sign up to follow @Novartis at <a href="https://twitter.com/novartisnews">https://twitter.com/novartisnews</a> For Novartis multimedia content, please visit <a href="https://www.novartis.com/news/media-library">https://www.novartis.com/news/media-library</a> For questions about the site or required registration, please contact <a href="mailto:media.relations@novartis.com">media.relations@novartis.com</a>References1. Novartis data on file. 2. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377‐85. 3. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology&ndash;National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020; 82:161-201. 4. Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; July 2020. 5. Baraliakos X, Braun J, Deodhar AA,et al. Long-term evaluation of secukinumab in ankylosing spondylitis: 5-year efficacy and safety results from a Phase 3 trial. Presented as a late-breaking abstract at the American College of Rheumatology Annual Meeting; October 19&ndash;24, 2018; Chicago, IL. 6. Bissonnette R, Luger T, Tha&ccedil;i D, et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile through 5 years of treatment in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2018;32:1507-14. 7. Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020;2(1):18-25. 8. Fortina AB, Bardazzi F, Berti S, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr. 2017;176(10):1339-54. 9. World Health Organization. Global report on psoriasis [online] 2016. Available from: https://apps.who.int/iris/handle/10665/204417 [Last accessed: July 2020]. 10. Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979-87. 11. Girolomoni G, Mrowietz U, Paul C, et al. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012; 167:717-24. 12. Sieper J, Poddubnyy D, Miossec P. The IL-23&ndash;IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019; 15:747-57. 13. Jansen DT, Hameetman M, van Bergen J, et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology (Oxford). 2015;54(4):728-35. 14. Data on file. CAIN457F2310 (MEASURE 2): 5 Year Report. Novartis Pharmaceuticals Corp; September 15, 2015. 15. Data on file. Data Analysis Report: Study CAIN457A2302E1. Novartis Pharmaceuticals Corp; November 30, 2015. 16. Marzo-Ortega H, Sieper J, Kivitz A. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2:e339-46. 17. Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals Corp; November 2008. 18. Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018. 19. Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008.<table><tbody><tr><td>Antonio Ligi Novartis Global External Communications +41 61 324 1374 (direct) <a href="mailto:antonio.ligi@novartis.com">antonio.ligi@novartis.com</a> Eric Althoff Novartis US External Communications +1 646 438 4335 <a href="mailto:eric.althoff@novartis.com">eric.althoff@novartis.com</a></td><td>Louise Clark Novartis Pharma Communications +41 61 324 2970 (direct) <a href="mailto:louise.clark@novartis.com">louise.clark@novartis.com </a></td></tr></tbody></table>Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: <a href="mailto:investor.relations@novartis.com">investor.relations@novartis.com</a><table><tbody><tr><td>Samir Shah</td><td>+41 61 324 7944</td><td>Sloan Simpson</td><td>+1 862 778 5052</td></tr></tbody></table>

Novartis, a leader in immuno-dermatology and rheumatology, today announced the European Commission (EC) has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years.

Novartis Cosentyx® Receives EU Approval for First-Line Systemic Treatment in Pediatric Psoriasis

Key takeaways:
Although banned in hand soaps, some consumer goods still include triclosan.
Rises in childhood urinary triclosan concentration were met with a heightened risk for eczema and allergic rhinitis symptoms.
As the urinary concentration of triclosan during childhood went up, so did a child’s risk for eczema and allergic rhinitis, according

Childhood exposure to antimicrobial linked to elevated risk for eczema, allergic rhinitis

In an interview with OncLive®, Qian (Janie) Qin, MD, highlighted the importance of early somatic and germline testing to inform subsequent treatment decisions for patients who with metastatic hormone-sensistive prostate cancer (mHSPC) who develop metastatic castration-resistant prostate cancer (mCRPC); reviewed pivotal trials supporting PARP inhibi

HARMONY Study Aims to Personalize PARP Inhibition in mHSPC Through Adaptive Design, Diverse Patient Enrollment

WhiteBlackRedGreenBlueYellowMagentaCyanOpaqueSemi-TransparentBlackWhiteRedGreenBlueYellowMagentaCyanOpaqueSemi-TransparentTransparentBlackWhiteRedGreenBlueYellowMagentaCyanTransparentSemi-TransparentOpaque
50%75%100%125%150%175%200%300%400%NoneRaisedDepressedUniformDropshadowProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace Ser

Real-World Data of SOC Cilta-Cel in R/R MM and Cilta-Cel in Patients With High-Risk Features

First-line treatment with the combination of osimertinib (Tagrisso) in combination with chemotherapy led to a statistically significant and clinically meaningful improvement in overall survival (OS) compared with osimertinib alone in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, according

First-Line Osimertinib Plus Chemo Boosts OS in EGFR+ NSCLC

KRAS G12C mutations may be associated with a poorer prognosis with standard first-line chemotherapy regimens for patients with metastatic colorectal cancer (mCRC), according to Cathy Eng, MD.
In a poster presentation at the 2025 ESMO Gastrointestinal Cancers Congress, Eng and colleagues shared results from a retrospective real-world analysis evalua

Real-World Analysis Highlights Potential Prognostic Impact of KRAS G12C Mutations in First-Line mCRC

Intravitreal ceftazidime may help treat syphilitic uveitis when IV penicillin is delayed.
Ceftazidime is not a substitute for IV penicillin, which is the preferred treatment.
A case series reported that 14 eyes showed improved inflammation with nine eyes gaining an average of 5.4 lines of vision.
Intravitreal injections with the antibiotic ceftazid

When Systemic Therapy Is Delayed for Syphilitic Uveitis, Ceftazidime May Help

A new Guillain-Barré syndrome mimic that appeared to be triggered by mild infection emerged in children with biallelic RCC1 variants, a case series showed.
One of the first cases was seen in a previously fit and well 7-month-old British Pakistani girl who presented with a rapid onset of ascending flaccid paralysis with areflexia following a fever a

Novel Guillain-Barre Mimic Emerges in Kids With Certain Gene Variants

Aluminum-adsorbed vaccines not tied to chronic diseases in kids, large study shows
Aluminum-adsorbed vaccines were not associated with the development of chronic diseases in youth, according to a large study published in Annals of Internal Medicine.
Common cold incidence decreased by more than 50% during pandemic
FDA approves simplified prefilled s

Vaccination

The FDA recently approved gepotidacin oral tablets (Blujepa; GSK) for the treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis in girls and women 12 years and older who weigh at least 40 kg. The approval als

Blujepa From GSK

Key Takeaways
The INDEPENDENCE trial did not achieve its primary endpoint of RBC transfusion independence over 12 weeks, but showed clinically meaningful improvements in secondary endpoints.
Luspatercept demonstrated a reduction in transfusion burden and an increase in hemoglobin levels, suggesting potential benefits for myelofibrosis-associated an

Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia

HealthDay News — Slightly higher levels of cardiac biomarkers may predict an increased risk for incident cancer, according to a study published online in the July issue of JACC: Advances.
Xinjiang Cai, M.D., Ph.D., from the University of California, Los Angeles, and colleagues examined the association between baseline levels of high-sensitivity car

Higher Cardiac Marker Levels Tied to Long-Term Cancer Risk

A global clinical trial has been launched to evaluate the oral therapy candidate BMS-986368 for treating spasticity — muscle stiffness and spasms — in people with multiple sclerosis (MS).
The Phase 2 study (NCT06782490), called BALANCE-MSS-1, will enroll about 200 adults with MS who have experienced spasticity for at least six months. The planned t

New global trial testing oral therapy BMS-986368 for MS spasticity

Although nirmatrelvir-ritonavir and molnupiravir have been linked to reduced risk for severe COVID-19 progression in outpatient settings, neither antiviral improved clinical outcomes for hospitalized patients when combined with usual care.
The addition of molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improvements in c

Molnupiravir, Nirmatrelvir-Ritonavir Not Supported for Inpatients With COVID-19

Treatment with belzutifan (Welireg) demonstrated a clinically meaningful and statistically significant improvement in quality-adjusted survival time vs everolimus (Afinitor) among patients with advanced renal cell carcinoma (RCC), according to findings from a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITES

Belzutifan Improves Quality-Adjusted Survival Time in Advanced RCC

Following the irradiation, the median size of the spleen of the patients went from 25 cm down to 22 cm, which was a significant reduction.
A low-dose splenic irradiation protocol before hematopoietic stem cell transplantation (HSCT) led to a substantial reduction in spleen size in patients with myelofibrosis (MF) while having favorable engraftment

Low-Dose Splenic Irradiation Before HSCT Safe and Effective in MF

The FDA's CRL for glofitamab with GemOx in relapsed/refractory DLBCL was due to insufficient evidence from the STARGLO trial for U.S. approval.
STARGLO trial showed promising ORR and OS results for glofitamab, but safety concerns included higher adverse event rates compared to rituximab.
The FDA has issued a complete response letter (CRL) to the su

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

From 2019 to 2024, the annual number of publications related to AI in nursing decision-making increased from 8 to 60.
Research on artificial intelligence (AI) and its role in nursing decision-making are growing rapidly, with certain nations emerging as leaders. These findings were recently published in Nursing Reports.
Researchers conducted a syste

Research on AI in Nursing Decision-Making Grows, Globalizes, and Evolves

Contact

Advertise

Other industries

Empower vascular access teams with tools that streamline workflows, enhance teamwork, and improve outcomes.

Tools for Efficient Vascular Access | Salubrity Online

Gebauer’s Pain Ease® works in just 4-10 seconds!

Give patients the comfort they deserve

Ivenix Infusion System

You have several options—but you also have several reasons to choose one above the rest.
Learn more now.


Prescribing IVIg?

AVA Consensus Statement recommend adhesives like gum mastic to secure PIVC dressings and devices.